中國心連心化肥(01866.HK)完成收購瑞誠科技51%股權
格隆匯7月1日丨中國心連心化肥(01866.HK)宣佈,就有關收購新三板公司瑞誠科技(836437.OC)的51%股權,於2020年7月1日,該交易已完成,氫力能源已成為瑞誠科技的控股公司,瑞誠科技現由氫力能源擁有51%權益,為氫力能源的附屬公司。
瑞誠科技為2015年10月於中國註冊成立的股份有限公司,其主營業務為醫藥中間體及核苷類產品的研發、生產和銷售。截至2018年及2019年12月31日止財政年度,瑞誠科技的經審核綜合純利分別約為人民幣1600萬元及人民幣2900萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.